Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 244.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,389,847 shares of the company’s stock after acquiring an additional 985,845 shares during the period. Assenagon Asset Management S.A. owned approximately 0.12% of Teva Pharmaceutical Industries worth $25,045,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TEVA. Maple Rock Capital Partners Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 68.3% in the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after purchasing an additional 1,770,000 shares in the last quarter. Iron Triangle Partners LP grew its position in Teva Pharmaceutical Industries by 113.1% in the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after buying an additional 1,469,864 shares during the last quarter. Driehaus Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $23,115,000. Davidson Kempner Capital Management LP lifted its position in shares of Teva Pharmaceutical Industries by 152.5% during the 2nd quarter. Davidson Kempner Capital Management LP now owns 1,765,485 shares of the company’s stock valued at $28,689,000 after acquiring an additional 1,066,150 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Teva Pharmaceutical Industries by 13.4% during the 2nd quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after acquiring an additional 1,031,400 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 1.9 %

TEVA stock opened at $17.91 on Friday. The company has a 50 day moving average of $18.01 and a two-hundred day moving average of $16.76. The company has a market cap of $20.29 billion, a price-to-earnings ratio of -43.68, a PEG ratio of 1.32 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 12-month low of $8.10 and a 12-month high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, July 10th. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.